Article 12 Oct 2023 10 Years After Actavis, The Cases That Follow Tell A Story United States Anti-trust
Article 02 Oct 2023 D.C. Circuit Dismisses FTC Antitrust Suit: Exclusive Pharma Patent Licenses Remain Permissible Under The Patent Act United States Anti-trust
Article 03 Dec 2021 Xryem: Pharmaceutical Settlement Acceleration Clause Found Anticompetitive Due To Risk Of "Profit Crushing Competition" United States Anti-trust